We are deconvoluting the role of the human extracellular matrix (ECM) in healthy and diseased states to uncover new targets for fibrosis and solid tumours and to support the discovery and development of novel classes of therapeutics.

Our Technology

We have pioneered the world’s first human extracellular matrix-based drug discovery platform.

Our Programmes

We are developing a portfolio of programmes in fibrosis and solid tumours.

Our Partnerships

We have significant agreements with Takeda Pharmaceuticals and Morphic Therapeutics.

Our People

Our ambitious team has a wealth of technical and medical knowledge and a strong commercial mindset.

Latest News

Proprietary in vitro 3D tissue specific and disease specific screening

Our Programmes

We are developing a portfolio of programmes in fibrosis and solid tumours

Learn more

See our Partnerships

We work with pharma and biotech partners to utilise the full discovery potential of our platform

Learn more